



CORRECTION

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

César Serrano^{1,2,3}, Adrián Mariño-Enríquez¹, Derrick L. Tao¹, Julia Ketzer⁴, Grant Eilers¹, Meijun Zhu¹, Channing Yu^{2,5,11}, Aristotle M. Mannan⁵, Brian P. Rubin⁶, George D. Demetri^{2,7}, Chandrajit P. Raut^{2,8}, Ajia Presnell⁹, Arin McKinley⁹, Michael C. Heinrich¹⁰, Jeffrey T. Czaplinski², Ewa Sicinska¹⁰, Sebastian Bauer⁴, Suzanne George² and Jonathan A. Fletcher^{1,2}

British Journal of Cancer (2019) 121:281; <https://doi.org/10.1038/s41416-019-0487-5>

Correction to: *British Journal of Cancer* (2019) **120**, 612–620; <https://doi.org/10.1038/s41416-019-0389-6>; published online 22 February 2019.

The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following:

M.C.H. has the following competing interests to declare: Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare.

The authors apologise for any inconvenience this may have caused.

¹Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA; ²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; ³Sarcoma Translational Research Laboratory, Vall d'Hebron Institute of Oncology; Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain; ⁴Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; ⁵Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, MA, USA; ⁶Department of Molecular Genetics, Lerner Research Institute and Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH, USA; ⁷Ludwig Center for Cancer Research at Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; ⁸Division of Surgical Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, 75 Francis Street, Boston, MA, USA; ⁹Portland VA Medical Center and OHSU Knight Cancer Institute, Portland, Oregon, USA and ¹⁰Department of Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA, USA

Correspondence: César Serrano (cserrano@vhio.net) or Jonathan A. Fletcher (jfletcher@partners.org)

¹¹Present address: Daiichi Sankyo Inc., Basking Ridge, NJ, USA

These authors contributed equally: Suzanne George, Jonathan A. Fletcher.